判定

参考

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 糖尿病症例解説16：2種類の内服薬投与中のコントロール不良2型糖尿病を有する61歳男性 interactive diabetes case 16 a 61 year old man with uncontrolled type 2 diabetes on two oral agents
2. 糖尿病症例解説18：最近の食事変化を伴う2型糖尿病の61歳男性（栄養療法） interactive diabetes case 18 a 61 year old man with type 2 diabetes and a recent change in diet medical nutrition therapy
3. 乳児（生後90日未満）の発熱：マネージメント febrile infant younger than 90 days of age management
4. 乳児（生後90日未満）の発熱：外来での評価 febrile infant younger than 90 days of age outpatient evaluation
5. 中等度の心電図テスト intermediate ecg test

Chronic Gastritis Due to Helicobacter Pylori Associated with Increased Serum Levels of CA54/61: A Report of Three Cases.

Yagura T, Egawa S, Okano A, Mizukoshi K.
The American journal of case reports. 2018 Aug;19()951-955.
BACKGROUND The bacterial pathogen Helicobacter pylori (H. pylori) can cause chronic gastritis. CA54/61 is a serum tumor marker that has been shown to be positive in the several types of human malignancy. However, the association of between chronic gastritis due to H. pylori and elevated serum levels
PMID 30104559

Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses.

Woolas RP, Conaway MR, Xu F, Jacobs IJ, Yu Y, Daly L, Davies AP, O'Briant K, Berchuck A, Soper JT.
Gynecologic oncology. 1995 Oct;59(1)111-6.
To determine whether measurement of the levels of multiple tumor markers in the preoperative serum of women presenting with a pelvic mass distinguished benign from malignant disease better than the assay of CA 125 alone, sera from 429 patients, 192 of whom had malignant histology, were assayed for 8
PMID 7557595

[Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].

Nozawa S, Udagawa Y, Sasaki H, Ito K, Akiya K, Terashima Y, Takamizawa H, Ohkura H, Fujimoto S, Hashimoto M.
Gan to kagaku ryoho. Cancer & chemotherapy. 1994 May;21(6)823-32.
Serum samples from patients with benign or malignant diseases were measured for the newly developed tumor markers CA54/61 and CA602 with the respective EIA kits for assessment of their utility as tumor markers. A total of 5236 patients were entered into the study, consisting of ovarian cancer patien
PMID 8185340

Specificity of a tumor marker (CA54/61) and its individual epitopes recognized by monoclonal antibodies, MA54 and MA61, in human tumor patients